In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in 2nd Review
THURSDAY, Sept. 8, 2022 (HealthDay News) – In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic lateral sclerosis). The FDA is not obligated to follow its advisors’ recommendations, though it usually does. Wednesday’s vote was 7-2Continue Reading